Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) Director Cyrus Harmon sold 15,000 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $9.41, for a total transaction of $141,150.00. Following the completion of the sale, the director now owns 791,283 shares of the company’s stock, valued at $7,445,973.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cyrus Harmon also recently made the following trade(s):
- On Monday, June 3rd, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.93, for a total transaction of $54,650.00.
- On Monday, May 6th, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.92, for a total transaction of $54,600.00.
- On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $9.51, for a total transaction of $142,650.00.
- On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.97, for a total transaction of $219,400.00.
Olema Pharmaceuticals Stock Performance
Shares of OLMA stock opened at $13.29 on Friday. Olema Pharmaceuticals, Inc. has a 52-week low of $6.01 and a 52-week high of $17.79. The firm has a fifty day moving average of $10.44 and a 200-day moving average of $12.17.
Institutional Investors Weigh In On Olema Pharmaceuticals
Large investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new stake in shares of Olema Pharmaceuticals in the 3rd quarter worth about $35,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth about $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth about $130,000. Caxton Associates LP bought a new stake in shares of Olema Pharmaceuticals in the 3rd quarter worth about $166,000. Finally, Entropy Technologies LP bought a new stake in shares of Olema Pharmaceuticals in the 1st quarter worth about $161,000. Institutional investors own 91.78% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms recently commented on OLMA. Capital One Financial reiterated an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Tuesday. Finally, The Goldman Sachs Group started coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $22.00.
Check Out Our Latest Stock Analysis on OLMA
Olema Pharmaceuticals Company Profile
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Stories
- Five stocks we like better than Olema Pharmaceuticals
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Novavax Stock’s Recent Surge and Future Potential
- Earnings Per Share Calculator: How to Calculate EPS
- Investing in Biotech: High Risk for a Potentially High Reward
- Business Services Stocks Investing
- GameStop Stock Update: What’s Driving Today’s Prices?
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.